Scalper1 News
Biotech Intercept Pharmaceuticals (ICPT) was riding high on an upgrade and multiple price-target increases after it issued new data late Monday on its fatty-liver-disease drug candidate. Intercept Pharma stock vaulted 31% in early trading on the stock market today, near 346, a four-month high. Monday’s data, which Intercept included in its Q2 financial report, provided more details on the mid-stage clinical trial of obetacholic acid (OCA) for Scalper1 News
Scalper1 News